董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Edward J. Sitar | 男 | Lead Independent Director | 62 | 13.16万美元 | 未持股 | 2023-05-01 |
| John Koconis | 男 | Chief Executive Officer and Chairman of the Board | 53 | 69.26万美元 | 未持股 | 2023-05-01 |
| David Cohen | 男 | Director | 58 | 11.36万美元 | 未持股 | 2023-05-01 |
| Lubor Gaal | 男 | Director | 55 | 10.74万美元 | 未持股 | 2023-05-01 |
| Gianluca Pirozzi | -- | Director | 46 | 10.89万美元 | 未持股 | 2023-05-01 |
| Edward J. Sitar | 男 | Lead Independent Director | 62 | 未披露 | 未持股 | 2023-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Koconis | 男 | Chief Executive Officer and Chairman of the Board | 53 | 69.26万美元 | 未持股 | 2023-05-01 |
| Joseph Lucchese | 男 | Chief Financial Officer, Executive Vice President, Treasurer and Secretary | 56 | 60.35万美元 | 未持股 | 2023-05-01 |
| Alan Mendelsohn | 男 | Chief Medical Officer and Executive Vice President | 61 | 56.84万美元 | 未持股 | 2023-05-01 |
董事简历
中英对照 | 中文 | 英文- Edward J. Sitar
-
Edward J. Sitar，2013年3月加入9 Meters Biopharma, Inc.之前，从2013年1月至2013年12月，Sita先生是Healthagen，一家Aetna公司的首席财务官。在Healthagen之前，2010年8月到2013年1月，Sita先生担任ActiveHealth管理，一家Aetna公司的执行副总裁兼首席财务官。2001年4月到2010年5月，他担任Cadent控股，一家私营，能为牙医和牙齿矫正者提供三维数字扫描服务公司的执行副总裁兼首席财务官。Sita先生1998年8月到2001年4月，担任MIM，现在BioScrip，一家上市专业制药和药物收益管理服务提供商公司的首席财务官和财务总监。1996年5月到1996年8月，Sitar先生是Vital Signs，一家上市专业的医疗产品制造商和经销商的金融副总裁。1993年6月到1996年4月，Sitar先生是Zenith的总会计师。1982年到1993年7月，他在Coopers & Lybrand，一家会计师事务所工作。他拥有斯克兰顿大学会计专业学士学位。
Edward J. Sitar, became 9 Meters Biopharma, Inc. Chief Financial Officer in July 2019. Most recently he served as the Chief Financial Officer of Ammon Analytical Laboratory, a company focused on specialty testing for the drug treatment community, from April 2017 to November 2018. Previously, he served as the Chief Financial Officer of Cancer Genetics, Inc. CGIX, a company focused on precision medicine for oncology, from March 2014 until February 2017. Prior to his service at Cancer Genetics, he served from January 2013 to December 2013 as the Chief Financial Officer-New Business of Healthagen, an Aetna company offering health products and services, and served as Chief Financial Officer of ActiveHealth Management from August 2010 to December 2012. From April 2001 to May 2010 he served as Executive Vice President and Chief Financial Officer of Cadent Holdings, Inc., a privately-held company that provided three-dimensional digital scanning services for dentists and orthodontists. From August 1998 to April 2001 Mr. Sitar served as Chief Financial Officer and Treasurer of MIM Corporation, now BioScrip, Inc., a publicly traded specialty pharmaceutical and pharmacy benefit management service provider. From May 1996 to August 1998 Mr. Sitar was the Vice President of Finance for Vital Signs, Inc., a publicly traded manufacturer and distributor of single use medical products. From June 1993 to April 1996 Mr. Sitar was the Controller of Zenith. From 1982 through July 1993 he was with Coopers & Lybrand, a public accounting firm. He holds a B.S. in accounting from the University of Scranton and is licensed as a Certified Public Accountant in New Jersey. - Edward J. Sitar，2013年3月加入9 Meters Biopharma, Inc.之前，从2013年1月至2013年12月，Sita先生是Healthagen，一家Aetna公司的首席财务官。在Healthagen之前，2010年8月到2013年1月，Sita先生担任ActiveHealth管理，一家Aetna公司的执行副总裁兼首席财务官。2001年4月到2010年5月，他担任Cadent控股，一家私营，能为牙医和牙齿矫正者提供三维数字扫描服务公司的执行副总裁兼首席财务官。Sita先生1998年8月到2001年4月，担任MIM，现在BioScrip，一家上市专业制药和药物收益管理服务提供商公司的首席财务官和财务总监。1996年5月到1996年8月，Sitar先生是Vital Signs，一家上市专业的医疗产品制造商和经销商的金融副总裁。1993年6月到1996年4月，Sitar先生是Zenith的总会计师。1982年到1993年7月，他在Coopers & Lybrand，一家会计师事务所工作。他拥有斯克兰顿大学会计专业学士学位。
- Edward J. Sitar, became 9 Meters Biopharma, Inc. Chief Financial Officer in July 2019. Most recently he served as the Chief Financial Officer of Ammon Analytical Laboratory, a company focused on specialty testing for the drug treatment community, from April 2017 to November 2018. Previously, he served as the Chief Financial Officer of Cancer Genetics, Inc. CGIX, a company focused on precision medicine for oncology, from March 2014 until February 2017. Prior to his service at Cancer Genetics, he served from January 2013 to December 2013 as the Chief Financial Officer-New Business of Healthagen, an Aetna company offering health products and services, and served as Chief Financial Officer of ActiveHealth Management from August 2010 to December 2012. From April 2001 to May 2010 he served as Executive Vice President and Chief Financial Officer of Cadent Holdings, Inc., a privately-held company that provided three-dimensional digital scanning services for dentists and orthodontists. From August 1998 to April 2001 Mr. Sitar served as Chief Financial Officer and Treasurer of MIM Corporation, now BioScrip, Inc., a publicly traded specialty pharmaceutical and pharmacy benefit management service provider. From May 1996 to August 1998 Mr. Sitar was the Vice President of Finance for Vital Signs, Inc., a publicly traded manufacturer and distributor of single use medical products. From June 1993 to April 1996 Mr. Sitar was the Controller of Zenith. From 1982 through July 1993 he was with Coopers & Lybrand, a public accounting firm. He holds a B.S. in accounting from the University of Scranton and is licensed as a Certified Public Accountant in New Jersey.
- John Koconis
-
John Koconis，担任Timber Pharmaceuticals, Inc.首席执行官，自2020年5月起担任Timber Pharmaceuticals, Inc.董事会董事，自2021年4月20日起担任Timber Pharmaceuticals, Inc.总裁兼董事会主席。Koconis先生此前曾于2019年6月至2020年4月担任公司全资子公司Timber Pharmaceuticals，LLC（“Timber Sub”）的首席执行官，并自2019年7月起担任Timber Sub的董事会成员。2016年7月至2019年1月，Koconis先生在生物制药公司Castle Creek制药有限责任公司担任执行副总裁兼首席商务官。在此之前，Koconis先生于2016年1月至2016年7月在生物技术公司赛诺菲 Genzyme担任皮肤科和呼吸科全球负责人。Koconis先生曾于2009年至2014年担任专业制药公司LEO Pharma Inc.的总裁兼首席执行官。Koconis先生获得了芝加哥洛约拉大学的生物学理学学士学位和芝加哥洛约拉大学昆兰商学院的MBA学位。
John Koconis,has served as Timber Pharmaceuticals, Inc. Chief Executive Officer, as a director on Timber Pharmaceuticals, Inc. Board since May 2020 and as Timber Pharmaceuticals, Inc. President and Chairman of the Board since April 20, 2021. Mr. Koconis previously served as Chief Executive Officer of Timber Pharmaceuticals, LLC, the Company's wholly-owned subsidiary ("Timber Sub") from June 2019 through April 2020 and has served on Timber Sub's board of managers since July 2019. From July 2016 to January 2019 Mr. Koconis served as Executive Vice President and Chief Commercial Officer at Castle Creek Pharmaceuticals LLC, a biopharmaceutical company. Prior to that, Mr. Koconis served as Global Lead for Dermatology & Respiratory at Sanofi Genzyme, a biotechnology company, from January 2016 to July 2016. Mr. Koconis served as President and Chief Executive Officer of LEO Pharma Inc., a specialty pharmaceutical company, from 2009 to 2014. Mr. Koconis received a Bachelor of Science in Biology from Loyola University Chicago and an MBA from the Quinlan School of Business at Loyola University Chicago. - John Koconis，担任Timber Pharmaceuticals, Inc.首席执行官，自2020年5月起担任Timber Pharmaceuticals, Inc.董事会董事，自2021年4月20日起担任Timber Pharmaceuticals, Inc.总裁兼董事会主席。Koconis先生此前曾于2019年6月至2020年4月担任公司全资子公司Timber Pharmaceuticals，LLC（“Timber Sub”）的首席执行官，并自2019年7月起担任Timber Sub的董事会成员。2016年7月至2019年1月，Koconis先生在生物制药公司Castle Creek制药有限责任公司担任执行副总裁兼首席商务官。在此之前，Koconis先生于2016年1月至2016年7月在生物技术公司赛诺菲 Genzyme担任皮肤科和呼吸科全球负责人。Koconis先生曾于2009年至2014年担任专业制药公司LEO Pharma Inc.的总裁兼首席执行官。Koconis先生获得了芝加哥洛约拉大学的生物学理学学士学位和芝加哥洛约拉大学昆兰商学院的MBA学位。
- John Koconis,has served as Timber Pharmaceuticals, Inc. Chief Executive Officer, as a director on Timber Pharmaceuticals, Inc. Board since May 2020 and as Timber Pharmaceuticals, Inc. President and Chairman of the Board since April 20, 2021. Mr. Koconis previously served as Chief Executive Officer of Timber Pharmaceuticals, LLC, the Company's wholly-owned subsidiary ("Timber Sub") from June 2019 through April 2020 and has served on Timber Sub's board of managers since July 2019. From July 2016 to January 2019 Mr. Koconis served as Executive Vice President and Chief Commercial Officer at Castle Creek Pharmaceuticals LLC, a biopharmaceutical company. Prior to that, Mr. Koconis served as Global Lead for Dermatology & Respiratory at Sanofi Genzyme, a biotechnology company, from January 2016 to July 2016. Mr. Koconis served as President and Chief Executive Officer of LEO Pharma Inc., a specialty pharmaceutical company, from 2009 to 2014. Mr. Koconis received a Bachelor of Science in Biology from Loyola University Chicago and an MBA from the Quinlan School of Business at Loyola University Chicago.
- David Cohen
-
David Cohen，自2020年8月起担任Timber Pharmaceuticals, Inc.董事会董事。科恩博士是纽约大学医学院皮肤病学Charles C. and Dorothea E. Harris教授，他还担任该学院运营和战略执行副主席，以及临床事务副主席。科恩博士于1994年加入纽约大学教职员工，他的工作重点是皮肤对外源性和光反应性化学物质的过敏和毒性反应，以及环境压力源对皮肤的相互作用。他目前担任私营研发公司Evommune，Inc.的董事会成员。科恩博士获得纽约城市大学生物医学科学理学学士学位、纽约州立大学石溪医学院医学博士学位和哥伦比亚大学公共卫生学院环境科学硕士学位。
David Cohen,has served as a director on Timber Pharmaceuticals, Inc. Board since August 2020. Dr. Cohen is the Charles C. and Dorothea E. Harris Professor of Dermatology at New York University School of Medicine, where he also serves as Executive Vice Chairman for Operations and Strategy, and Vice Chairman of Clinical Affairs. Dr. Cohen joined the NYU faculty in 1994 and his work has concentrated on cutaneous allergic and toxic reactions to exogenous and photo-reactive chemicals and the interaction of environmental stressors on the skin. He currently serves on the board of directors of Evommune, Inc., a private research and development company. Dr. Cohen received a Bachelor of Science in biomedical science from the City University of New York, an M.D. from State University of New York at Stony Brook School of Medicine and an M.P.H. in environmental science from Columbia University School of Public Health. - David Cohen，自2020年8月起担任Timber Pharmaceuticals, Inc.董事会董事。科恩博士是纽约大学医学院皮肤病学Charles C. and Dorothea E. Harris教授，他还担任该学院运营和战略执行副主席，以及临床事务副主席。科恩博士于1994年加入纽约大学教职员工，他的工作重点是皮肤对外源性和光反应性化学物质的过敏和毒性反应，以及环境压力源对皮肤的相互作用。他目前担任私营研发公司Evommune，Inc.的董事会成员。科恩博士获得纽约城市大学生物医学科学理学学士学位、纽约州立大学石溪医学院医学博士学位和哥伦比亚大学公共卫生学院环境科学硕士学位。
- David Cohen,has served as a director on Timber Pharmaceuticals, Inc. Board since August 2020. Dr. Cohen is the Charles C. and Dorothea E. Harris Professor of Dermatology at New York University School of Medicine, where he also serves as Executive Vice Chairman for Operations and Strategy, and Vice Chairman of Clinical Affairs. Dr. Cohen joined the NYU faculty in 1994 and his work has concentrated on cutaneous allergic and toxic reactions to exogenous and photo-reactive chemicals and the interaction of environmental stressors on the skin. He currently serves on the board of directors of Evommune, Inc., a private research and development company. Dr. Cohen received a Bachelor of Science in biomedical science from the City University of New York, an M.D. from State University of New York at Stony Brook School of Medicine and an M.P.H. in environmental science from Columbia University School of Public Health.
- Lubor Gaal
-
Lubor Gaal，自2020年8月起担任Timber Pharmaceuticals, Inc.董事会董事。Gaal博士在欧洲和美国的生物技术和制药公司拥有超过20年的工作经验。截至2022年3月，Gaal博士是Targovax的首席财务官，Targovax是一家上市的肿瘤生物技术公司，专注于开发免疫肿瘤医学和RNA疗法。Gaal博士此前曾于2018年7月至2022年3月担任全球生命科学交易公司Locust Walk的董事总经理。在加入Locust Walk之前，他是全球领先的皮肤病学公司Almirall的外部创新和许可负责人以及研发管理委员会成员。Gaal博士曾在百时美施贵宝以及拜耳集团担任多个高级业务发展职位。除了在制药公司的长期经验，他还曾在Neuro3d和Vectron Therapeutics这两家欧洲生物技术公司担任执行管理职务。他的职业生涯始于加利福尼亚州，在那里他在加利福尼亚州旧金山的Burrill & Co.为生物技术和制药公司提供战略和交易方面的建议。Gaal博士拥有加州大学伯克利分校神经科学博士学位。
Lubor Gaal,has served as a director on Timber Pharmaceuticals, Inc. Board since August 2020. Dr. Gaal has over 20 years of experience working for biotech and pharmaceutical companies in Europe and the United States. As of March 2022, Dr. Gaal is the Chief Financial Officer of Targovax, a publicly listed oncology biotechnology company focused on developing immune-oncology medicine and RNA therapeutics. Dr. Gaal previously worked as the Managing Director of Locust Walk, a global life science transaction firm, from July 2018 to March 2022. Prior to Locust Walk, he was the Head of External Innovation and Licensing and a member of the R&D Management Committee at Almirall, a leading Dermatology company globally. Dr. Gaal held various senior business development positions at Bristol-Myers Squibb as well as Bayer AG. In addition to his long experience in pharmaceutical companies, he also held executive management roles at Neuro3d and Vectron therapeutics, two European biotech companies. He started his career in California, where he advised biotech and pharma companies on strategy and transactions at Burrill & Co. in San Francisco, California. Dr. Gaal has a Ph.D. in Neurosciences from the University of California in Berkeley, California. - Lubor Gaal，自2020年8月起担任Timber Pharmaceuticals, Inc.董事会董事。Gaal博士在欧洲和美国的生物技术和制药公司拥有超过20年的工作经验。截至2022年3月，Gaal博士是Targovax的首席财务官，Targovax是一家上市的肿瘤生物技术公司，专注于开发免疫肿瘤医学和RNA疗法。Gaal博士此前曾于2018年7月至2022年3月担任全球生命科学交易公司Locust Walk的董事总经理。在加入Locust Walk之前，他是全球领先的皮肤病学公司Almirall的外部创新和许可负责人以及研发管理委员会成员。Gaal博士曾在百时美施贵宝以及拜耳集团担任多个高级业务发展职位。除了在制药公司的长期经验，他还曾在Neuro3d和Vectron Therapeutics这两家欧洲生物技术公司担任执行管理职务。他的职业生涯始于加利福尼亚州，在那里他在加利福尼亚州旧金山的Burrill & Co.为生物技术和制药公司提供战略和交易方面的建议。Gaal博士拥有加州大学伯克利分校神经科学博士学位。
- Lubor Gaal,has served as a director on Timber Pharmaceuticals, Inc. Board since August 2020. Dr. Gaal has over 20 years of experience working for biotech and pharmaceutical companies in Europe and the United States. As of March 2022, Dr. Gaal is the Chief Financial Officer of Targovax, a publicly listed oncology biotechnology company focused on developing immune-oncology medicine and RNA therapeutics. Dr. Gaal previously worked as the Managing Director of Locust Walk, a global life science transaction firm, from July 2018 to March 2022. Prior to Locust Walk, he was the Head of External Innovation and Licensing and a member of the R&D Management Committee at Almirall, a leading Dermatology company globally. Dr. Gaal held various senior business development positions at Bristol-Myers Squibb as well as Bayer AG. In addition to his long experience in pharmaceutical companies, he also held executive management roles at Neuro3d and Vectron therapeutics, two European biotech companies. He started his career in California, where he advised biotech and pharma companies on strategy and transactions at Burrill & Co. in San Francisco, California. Dr. Gaal has a Ph.D. in Neurosciences from the University of California in Berkeley, California.
- Gianluca Pirozzi
-
Gianluca Pirozzi，自2020年5月起担任Timber Pharmaceuticals, Inc.董事会董事。Pirozzi博士是一位临床免疫学家，在制药行业拥有超过20年的经验。自2019年10月起，Pirozzi博士担任致力于罕见病开发的全球生物制药公司亚力兄制药（纳斯达克：ALXN）的高级副总裁、临床开发和转化科学负责人。在此之前，Pirozzi博士曾于2018年7月至2019年9月在全球生物制药公司赛诺菲-健赞（纳斯达克：SNY）担任罕见病和转化基因治疗的开发主管，并于2013年至2018年担任Dupixent的全球项目主管。Pirozzi博士还自2018年9月起担任Imbria Pharmaceuticals的董事会成员，并自2015年12月起担任SMS Research Foundation的科学顾问。Pirozzi博士拥有Universit à Campus Bio-Medico di Roma的医学博士学位和Sapienza Universit à di Roma的免疫学博士学位，并在法国巴黎的巴斯德研究所完成了免疫学博士后学位。
Gianluca Pirozzi,has served as a director on Timber Pharmaceuticals, Inc. Board since May 2020. Dr. Pirozzi is a clinical immunologist with over 20 years of experience in the pharmaceutical industry. Since October 2019, Dr. Pirozzi has served as SVP, Head of Clinical Development and Translational Sciences at Alexion Pharmaceuticals (Nasdaq: ALXN), a global biopharmaceutical company dedicated to Rare Disease Development. Prior to that, Dr. Pirozzi served as Head of Development for Rare Diseases and Translational Gene Therapy at Sanofi-Genzyme (Nasdaq: SNY), a global biopharmaceutical company from July 2018 to September 2019, and as Global Project Head of Dupixent from 2013 to 2018. Dr. Pirozzi has also served on the board of directors of Imbria Pharmaceuticals since September 2018 and has been a scientific advisor of SMS Research Foundation since December 2015. Dr. Pirozzi holds an M.D. from Università Campus Bio-Medico di Roma and a Ph.D. in Immunology from Sapienza Università di Roma and completed a Post-Doc in Immunology at the Pasteur Institute in Paris, France. - Gianluca Pirozzi，自2020年5月起担任Timber Pharmaceuticals, Inc.董事会董事。Pirozzi博士是一位临床免疫学家，在制药行业拥有超过20年的经验。自2019年10月起，Pirozzi博士担任致力于罕见病开发的全球生物制药公司亚力兄制药（纳斯达克：ALXN）的高级副总裁、临床开发和转化科学负责人。在此之前，Pirozzi博士曾于2018年7月至2019年9月在全球生物制药公司赛诺菲-健赞（纳斯达克：SNY）担任罕见病和转化基因治疗的开发主管，并于2013年至2018年担任Dupixent的全球项目主管。Pirozzi博士还自2018年9月起担任Imbria Pharmaceuticals的董事会成员，并自2015年12月起担任SMS Research Foundation的科学顾问。Pirozzi博士拥有Universit à Campus Bio-Medico di Roma的医学博士学位和Sapienza Universit à di Roma的免疫学博士学位，并在法国巴黎的巴斯德研究所完成了免疫学博士后学位。
- Gianluca Pirozzi,has served as a director on Timber Pharmaceuticals, Inc. Board since May 2020. Dr. Pirozzi is a clinical immunologist with over 20 years of experience in the pharmaceutical industry. Since October 2019, Dr. Pirozzi has served as SVP, Head of Clinical Development and Translational Sciences at Alexion Pharmaceuticals (Nasdaq: ALXN), a global biopharmaceutical company dedicated to Rare Disease Development. Prior to that, Dr. Pirozzi served as Head of Development for Rare Diseases and Translational Gene Therapy at Sanofi-Genzyme (Nasdaq: SNY), a global biopharmaceutical company from July 2018 to September 2019, and as Global Project Head of Dupixent from 2013 to 2018. Dr. Pirozzi has also served on the board of directors of Imbria Pharmaceuticals since September 2018 and has been a scientific advisor of SMS Research Foundation since December 2015. Dr. Pirozzi holds an M.D. from Università Campus Bio-Medico di Roma and a Ph.D. in Immunology from Sapienza Università di Roma and completed a Post-Doc in Immunology at the Pasteur Institute in Paris, France.
- Edward J. Sitar
-
Edward J. Sitar，自2020年5月起担任Timber Pharmaceuticals, Inc.董事会董事。Sitar先生拥有丰富的财务领导经验。截至2022年1月18日，Sitar先生的首席财务官任职于Variantyx，Inc.，这是一家新兴的诊断公司。Sitar先生曾担任9 Meters Biopharma，Inc.（前身为Innovate Biopharmaceuticals Inc.（纳斯达克：NMTR）的首席财务官，该公司是一家临床阶段的生物技术公司。在此之前，他曾在科技公司CareDox，Inc.担任代理首席财务官，在专注于药物治疗界专业检测的公司Ammon Analytical Laboratory担任首席财务官，在专注于肿瘤精准医学的公司Vyant Bio, Inc.（f/k/a Cancer Genetics, Inc.）（纳斯达克：VYNT）担任首席财务官的TERM2。Sitar先生拥有斯克兰顿大学会计学理学学士学位，并拥有新泽西州注册会计师执照。
Edward J. Sitar,has served as a director on Timber Pharmaceuticals, Inc. Board since May 2020. Mr. Sitar has had extensive financial leadership experience. As of January 18, 2022, Mr. Sitar is the Chief Financial Officer of Variantyx, Inc., an emerging diagnostic company. Mr. Sitar has served as the Chief Financial Officer of 9 Meters Biopharma, Inc. formerly known as Innovate Biopharmaceuticals Inc. (Nasdaq: NMTR), a clinical stage biotechnology company. Prior to that, he served as Acting Chief Financial Officer of CareDox, Inc., a technology company, as the Chief Financial Officer of Ammon Analytical Laboratory, a company focused on specialty testing for the drug treatment community and as the Chief Financial Officer of Vyant Bio, Inc. (f/k/a Cancer Genetics, Inc.) (Nasdaq: VYNT), a company focused on precision medicine for oncology Mr. Sitar holds a Bachelor of Science in accounting from the University of Scranton and is licensed as a Certified Public Accountant in New Jersey. - Edward J. Sitar，自2020年5月起担任Timber Pharmaceuticals, Inc.董事会董事。Sitar先生拥有丰富的财务领导经验。截至2022年1月18日，Sitar先生的首席财务官任职于Variantyx，Inc.，这是一家新兴的诊断公司。Sitar先生曾担任9 Meters Biopharma，Inc.（前身为Innovate Biopharmaceuticals Inc.（纳斯达克：NMTR）的首席财务官，该公司是一家临床阶段的生物技术公司。在此之前，他曾在科技公司CareDox，Inc.担任代理首席财务官，在专注于药物治疗界专业检测的公司Ammon Analytical Laboratory担任首席财务官，在专注于肿瘤精准医学的公司Vyant Bio, Inc.（f/k/a Cancer Genetics, Inc.）（纳斯达克：VYNT）担任首席财务官的TERM2。Sitar先生拥有斯克兰顿大学会计学理学学士学位，并拥有新泽西州注册会计师执照。
- Edward J. Sitar,has served as a director on Timber Pharmaceuticals, Inc. Board since May 2020. Mr. Sitar has had extensive financial leadership experience. As of January 18, 2022, Mr. Sitar is the Chief Financial Officer of Variantyx, Inc., an emerging diagnostic company. Mr. Sitar has served as the Chief Financial Officer of 9 Meters Biopharma, Inc. formerly known as Innovate Biopharmaceuticals Inc. (Nasdaq: NMTR), a clinical stage biotechnology company. Prior to that, he served as Acting Chief Financial Officer of CareDox, Inc., a technology company, as the Chief Financial Officer of Ammon Analytical Laboratory, a company focused on specialty testing for the drug treatment community and as the Chief Financial Officer of Vyant Bio, Inc. (f/k/a Cancer Genetics, Inc.) (Nasdaq: VYNT), a company focused on precision medicine for oncology Mr. Sitar holds a Bachelor of Science in accounting from the University of Scranton and is licensed as a Certified Public Accountant in New Jersey.
高管简历
中英对照 | 中文 | 英文- John Koconis
John Koconis，担任Timber Pharmaceuticals, Inc.首席执行官，自2020年5月起担任Timber Pharmaceuticals, Inc.董事会董事，自2021年4月20日起担任Timber Pharmaceuticals, Inc.总裁兼董事会主席。Koconis先生此前曾于2019年6月至2020年4月担任公司全资子公司Timber Pharmaceuticals，LLC（“Timber Sub”）的首席执行官，并自2019年7月起担任Timber Sub的董事会成员。2016年7月至2019年1月，Koconis先生在生物制药公司Castle Creek制药有限责任公司担任执行副总裁兼首席商务官。在此之前，Koconis先生于2016年1月至2016年7月在生物技术公司赛诺菲 Genzyme担任皮肤科和呼吸科全球负责人。Koconis先生曾于2009年至2014年担任专业制药公司LEO Pharma Inc.的总裁兼首席执行官。Koconis先生获得了芝加哥洛约拉大学的生物学理学学士学位和芝加哥洛约拉大学昆兰商学院的MBA学位。
John Koconis,has served as Timber Pharmaceuticals, Inc. Chief Executive Officer, as a director on Timber Pharmaceuticals, Inc. Board since May 2020 and as Timber Pharmaceuticals, Inc. President and Chairman of the Board since April 20, 2021. Mr. Koconis previously served as Chief Executive Officer of Timber Pharmaceuticals, LLC, the Company's wholly-owned subsidiary ("Timber Sub") from June 2019 through April 2020 and has served on Timber Sub's board of managers since July 2019. From July 2016 to January 2019 Mr. Koconis served as Executive Vice President and Chief Commercial Officer at Castle Creek Pharmaceuticals LLC, a biopharmaceutical company. Prior to that, Mr. Koconis served as Global Lead for Dermatology & Respiratory at Sanofi Genzyme, a biotechnology company, from January 2016 to July 2016. Mr. Koconis served as President and Chief Executive Officer of LEO Pharma Inc., a specialty pharmaceutical company, from 2009 to 2014. Mr. Koconis received a Bachelor of Science in Biology from Loyola University Chicago and an MBA from the Quinlan School of Business at Loyola University Chicago.- John Koconis，担任Timber Pharmaceuticals, Inc.首席执行官，自2020年5月起担任Timber Pharmaceuticals, Inc.董事会董事，自2021年4月20日起担任Timber Pharmaceuticals, Inc.总裁兼董事会主席。Koconis先生此前曾于2019年6月至2020年4月担任公司全资子公司Timber Pharmaceuticals，LLC（“Timber Sub”）的首席执行官，并自2019年7月起担任Timber Sub的董事会成员。2016年7月至2019年1月，Koconis先生在生物制药公司Castle Creek制药有限责任公司担任执行副总裁兼首席商务官。在此之前，Koconis先生于2016年1月至2016年7月在生物技术公司赛诺菲 Genzyme担任皮肤科和呼吸科全球负责人。Koconis先生曾于2009年至2014年担任专业制药公司LEO Pharma Inc.的总裁兼首席执行官。Koconis先生获得了芝加哥洛约拉大学的生物学理学学士学位和芝加哥洛约拉大学昆兰商学院的MBA学位。
- John Koconis,has served as Timber Pharmaceuticals, Inc. Chief Executive Officer, as a director on Timber Pharmaceuticals, Inc. Board since May 2020 and as Timber Pharmaceuticals, Inc. President and Chairman of the Board since April 20, 2021. Mr. Koconis previously served as Chief Executive Officer of Timber Pharmaceuticals, LLC, the Company's wholly-owned subsidiary ("Timber Sub") from June 2019 through April 2020 and has served on Timber Sub's board of managers since July 2019. From July 2016 to January 2019 Mr. Koconis served as Executive Vice President and Chief Commercial Officer at Castle Creek Pharmaceuticals LLC, a biopharmaceutical company. Prior to that, Mr. Koconis served as Global Lead for Dermatology & Respiratory at Sanofi Genzyme, a biotechnology company, from January 2016 to July 2016. Mr. Koconis served as President and Chief Executive Officer of LEO Pharma Inc., a specialty pharmaceutical company, from 2009 to 2014. Mr. Koconis received a Bachelor of Science in Biology from Loyola University Chicago and an MBA from the Quinlan School of Business at Loyola University Chicago.
- Joseph Lucchese
Joseph Lucchese，自2020年5月起担任Timber Pharmaceuticals, Inc.首席财务官。Lucchese先生还在2020年1月至2021年10月期间担任TardiMed Sciences LLC（“TardiMed”）的合伙人。在加入TardiMed之前，2015年7月至2020年1月，他是Oncology Partners LLC的创始成员和董事总经理，该公司是一家服务于发展阶段生物技术公司和投资者的精品金融咨询公司。Lucchese先生还曾于2019年1月至2020年1月担任ASR集团的董事总经理，该集团是Oncology Partners的一个部门，专注于通过并购或许可交易实现生物技术资产的价值最大化。在创立Oncology Partners LLC之前，Lucchese先生是Foundation Ventures的管理合伙人，该公司是一家为早期生命科学公司提供服务的投资银行公司。
Joseph Lucchese,has served as Timber Pharmaceuticals, Inc. Chief Financial Officer since May 2020. Mr. Lucchese also served as a Partner at TardiMed Sciences LLC ("TardiMed") from January 2020 until October 2021. Prior to joining TardiMed, he was a founding member and Managing Director of Oncology Partners LLC, a boutique financial advisory firm serving development stage biotechnology companies and investors, from July 2015 to January 2020. Mr. Lucchese also served as the Managing Director of The ASR Group, a division of Oncology Partners which focuses on value maximization of biotechnology assets via M&A or licensing transactions, from January 2019 to January 2020. Prior to founding Oncology Partners LLC, Mr. Lucchese was a Managing Partner of Foundation Ventures, an investment banking firm servicing early life sciences companies.- Joseph Lucchese，自2020年5月起担任Timber Pharmaceuticals, Inc.首席财务官。Lucchese先生还在2020年1月至2021年10月期间担任TardiMed Sciences LLC（“TardiMed”）的合伙人。在加入TardiMed之前，2015年7月至2020年1月，他是Oncology Partners LLC的创始成员和董事总经理，该公司是一家服务于发展阶段生物技术公司和投资者的精品金融咨询公司。Lucchese先生还曾于2019年1月至2020年1月担任ASR集团的董事总经理，该集团是Oncology Partners的一个部门，专注于通过并购或许可交易实现生物技术资产的价值最大化。在创立Oncology Partners LLC之前，Lucchese先生是Foundation Ventures的管理合伙人，该公司是一家为早期生命科学公司提供服务的投资银行公司。
- Joseph Lucchese,has served as Timber Pharmaceuticals, Inc. Chief Financial Officer since May 2020. Mr. Lucchese also served as a Partner at TardiMed Sciences LLC ("TardiMed") from January 2020 until October 2021. Prior to joining TardiMed, he was a founding member and Managing Director of Oncology Partners LLC, a boutique financial advisory firm serving development stage biotechnology companies and investors, from July 2015 to January 2020. Mr. Lucchese also served as the Managing Director of The ASR Group, a division of Oncology Partners which focuses on value maximization of biotechnology assets via M&A or licensing transactions, from January 2019 to January 2020. Prior to founding Oncology Partners LLC, Mr. Lucchese was a Managing Partner of Foundation Ventures, an investment banking firm servicing early life sciences companies.
- Alan Mendelsohn
Alan Mendelsohn，自2021年2月起担任Timber Pharmaceuticals, Inc.首席医疗官。Mendelsohn博士是一位获得董事会认证的儿科心脏病专家，在临床开发和医疗事务方面拥有超过20年的经验。加入公司前，自2016年12月起担任Sun Pharmaceuticals Industries Limited皮肤科医疗事务副总裁。Mendelsohn博士还于2014年11月至2016年12月担任辉瑞高级总监，并于2006年11月至2014年1月担任杨森制药免疫学研发高级总监。他还曾在强生（NYSE：JNJ）旗下公司Centocor Inc.担任过各种领导职务。Mendelsohn博士拥有布鲁克林纽约州立大学健康科学中心的医学博士学位。
Alan Mendelsohn,has served as Timber Pharmaceuticals, Inc. Chief Medical Officer since February 2021. Dr. Mendelsohn is a board-certified pediatric cardiologist with over 20 years of experience in clinical development and medical affairs. Prior to joining the Company, he served as Associate Vice President of Dermatology Medical Affairs for Sun Pharmaceuticals Industries Limited since December 2016. Dr. Mendelsohn has also served as Senior Director at Pfizer from November 2014 through December 2016 as well as Senior Director of Immunology Research and Development for Janssen Pharmaceuticals from November 2006 through January 2014. He has also served in various leadership roles at Centocor Inc., a Johnson & Johnson (NYSE: JNJ) company. Dr. Mendelsohn holds an M.D. from the State University of New York Health Science Center at Brooklyn.- Alan Mendelsohn，自2021年2月起担任Timber Pharmaceuticals, Inc.首席医疗官。Mendelsohn博士是一位获得董事会认证的儿科心脏病专家，在临床开发和医疗事务方面拥有超过20年的经验。加入公司前，自2016年12月起担任Sun Pharmaceuticals Industries Limited皮肤科医疗事务副总裁。Mendelsohn博士还于2014年11月至2016年12月担任辉瑞高级总监，并于2006年11月至2014年1月担任杨森制药免疫学研发高级总监。他还曾在强生（NYSE：JNJ）旗下公司Centocor Inc.担任过各种领导职务。Mendelsohn博士拥有布鲁克林纽约州立大学健康科学中心的医学博士学位。
- Alan Mendelsohn,has served as Timber Pharmaceuticals, Inc. Chief Medical Officer since February 2021. Dr. Mendelsohn is a board-certified pediatric cardiologist with over 20 years of experience in clinical development and medical affairs. Prior to joining the Company, he served as Associate Vice President of Dermatology Medical Affairs for Sun Pharmaceuticals Industries Limited since December 2016. Dr. Mendelsohn has also served as Senior Director at Pfizer from November 2014 through December 2016 as well as Senior Director of Immunology Research and Development for Janssen Pharmaceuticals from November 2006 through January 2014. He has also served in various leadership roles at Centocor Inc., a Johnson & Johnson (NYSE: JNJ) company. Dr. Mendelsohn holds an M.D. from the State University of New York Health Science Center at Brooklyn.